中文摘要：

目的研究乳腺癌转移抑制因子1（BRMS1）、整合素β1、p-AKT在卵巢癌中的表达及其与临床病理特征的关系。方法应用免疫组织化学法检测卵巢癌、良性肿瘤及其卵巢组织中BRMS1、整合素β1、p-AKT的表达。结果 BRMS1在卵巢癌中阳性表达率降低（P〈0.01）,其表达与卵巢癌转移相关,与组织学分级无关。整合素β1及p-AKT在卵巢癌中的阳性表达率升高（P〈0.01）,其表达与卵巢癌病理分期、分化程度有关（P〈0.05）。BRMS1与整合素β1及p-AKT在卵巢癌组织中表达呈负相关（r=-0.59,r=-0.50,P〈0.05）。结论卵巢癌中BRMS1有可能通过抑制整合素β1/AKT通路,抑制肿瘤转移。

英文摘要：

Objective To explore the expression of BRMS1and integrin β 1,p-AKT in ovarian cancer,and their relationships with clinicopathological features.Methods SP immanohistochemistrical method was utilized to detect the level of BRMS1,integrin β 1 and p-AKT in normal ovarian tissue,benign ovarian tumor and ovarian adenocarcinoma.Results BRMS1 positive expression in ovarian cancer was decreased（P＆lt;0.01）;Its expression was associated with ovarian cancer metastasis,had nothing to do with histologic grading.Integrin beta 1 and p-AKT in the positive expression rate of ovari an cancer increased（P＆lt;0.01）;Its expression was associated with ovarian cancer pathological staging and differentiation degree（P＆lt;0.05）.BRMS1 with integrin beta 1,p-AKT expressed in ovarian cancer tissue showed a negative correlation（r=-0.59,r=-0.50,P＆lt;0.05）.Conclusion BRMS1 might be in cooperation with integrin β 1 /p-AKT signal pathway to inhibit the metastasis function of the ovarian cancer.